beta-lactams has been researched along with Infections, Pseudomonas in 194 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (14.43) | 18.7374 |
| 1990's | 13 (6.70) | 18.2507 |
| 2000's | 51 (26.29) | 29.6817 |
| 2010's | 86 (44.33) | 24.3611 |
| 2020's | 16 (8.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Feng, Y; Hua, X; Ji, J; Ke, H; Li, Y; Moran, RA; Ruan, Z; Shen, H; van Schaik, W; Yu, Y; Zhou, W; Zhu, Y | 1 |
| Chen, X; Guo, S; Li, Y; Liang, X; Su, H; Tan, X; Xi, J | 1 |
| Calò, F; Cirillo, P; Coppola, N; Di Caprio, G; Macera, M; Onorato, L | 1 |
| Flume, PA; Goss, CH; Heltshe, SL; Sanders, DB; Skalland, M; VanDevanter, DR; West, NE | 1 |
| Chauhan, SM; Palsson, BO; Pogliano, J; Rajput, A; Rychel, K; Sastry, AV; Szubin, R; Tsunemoto, H | 1 |
| Del Pozo, JL; Pina-Sánchez, M; Rua, M | 1 |
| Dietert, JB; Hurst, EA; Ko, J | 1 |
| Guzman, OE; Hobbs, ALV; Shea, KM; Thabit, AK | 1 |
| Bodtger, U; Eklöf, J; Gliese, KM; Ingebrigtsen, TS; Jensen, JS | 1 |
| Hampton, NB; Kollef, MH; Micek, ST; Teshome, BF; Vouri, SM | 1 |
| Bellos, I; Karageorgiou, V; Pergialiotis, V; Perrea, DN | 1 |
| Ariza, J; Benavent, E; Cabo, X; Gómez-Junyent, J; Murillo, O; Padullés, A; Rigo-Bonnin, R; Soldevila, L; Tubau, F | 1 |
| Chen, D; Li, F; Li, L; Liang, D; Wang, F; Zhang, B | 1 |
| Bhalodi, AA; Gamage, D; Humphries, RM; Oppermann, N; Shamsheyeva, A; Sikorski, A | 1 |
| Ibrahim, D; Jabbour, JF; Kanj, SS | 1 |
| Broquet, A; Burghelea, A; Caroff, N; Crémet, L; Delanou, S; Leroy, AG; Muller, D; Roquilly, A | 1 |
| Holland, P; Jahnke, N | 1 |
| Akter, S; Hamasaki, C; Islam, W; Matsui, H; Migiyama, Y; Miyao, K; Ono, K; Sakagami, T; Sawa, T; Toyomoto, T; Tsutsuki, H; Yamaguchi, Y; Yamamoto, K; Zhang, T | 1 |
| Bhatt, J; Nevitt, SJ; Smyth, AR | 1 |
| McCarthy, KL; Paterson, DL | 1 |
| Barriga, Á; Bravo-Ferrer, J; Delgado, M; Lavín-Alconero, L; López-Cortés, LE; Lupión, C; Núñez-Núñez, M; Retamar, P; Rodríguez-Baño, J; Rosso-Fernández, C | 1 |
| Ha, DT; Ho-Le, TP; Hoang, HQ; Nguyen, DA; Nguyen, TA; Nguyen, TSM; Nguyen, TV; Pham, TTN; Tran, GM; Tran, NV; Tran-Nguyen, CH | 1 |
| Azimi, L; Rastegar Lari, A | 1 |
| Fung, CP; Lin, YT; Wang, FD; Wu, PF; Yang, TC | 1 |
| Al-Hasan, MN; Al-Jaghbeer, MJ; Bookstaver, PB; Hucks, J; Justo, JA; Kohn, J; Owens, W | 1 |
| Felix, LM; Kaehne, A; Marsden, PA; Milan, SJ; Sheridan, E; Spencer, S | 1 |
| Fosse, N; Frei, R; Tschudin-Sutter, S; Widmer, AF | 1 |
| Fluit, AC; Franssens, BT; Rentenaar, RJ | 1 |
| Clark, ST; Coburn, B; Donaldson, SL; Guttman, DS; Hwang, DM; Sinha, U; Tullis, DE; Wang, PW; Waters, VJ; Yau, YCW; Zhang, Y | 1 |
| Bidgood, LE; Coote, PJ; Murray, RM; Parcell, BJ; Siriyong, T; Voravuthikunchai, SP; Wright, F; Young, SA | 1 |
| Barceló, IM; Jordana-Lluch, E; Juan, C; Oliver, A; Sánchez-Diener, I; Torrens, G; Zamorano, L | 1 |
| Barbosa, C; Bewig, B; Bobis, I; Fickenscher, H; Franke, A; Friedrichs, A; Höppner, M; Krenz-Weinreich, A; Rosenstiel, P; Rühlemann, M; Schreiber, S; Schubert, S; Schulenburg, H; Tueffers, L | 1 |
| Bliziotis, IA; Falagas, ME; Tansarli, GS; Vardakas, KZ | 1 |
| Cavallo, JD; Fichant, G; Llanes, C; Mérens, A; Plésiat, P; Pourcel, C; Richardot, C | 1 |
| Fournier, D; Gbonon, V; Guessennd, N; Jeannot, K; Müller, E; Plésiat, P | 1 |
| Beumier, M; Casu, GS; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Block, CS; Cohen, MJ; Moses, AE; Nir-Paz, R | 1 |
| Hiraki, Y; Kawano, F; Matsui, M; Shibayama, K; Suzuki, M; Suzuki, S | 1 |
| Autenrieth, I; Buhl, M; Hölzl, F; Kaase, M; Lacher, A; Marschal, M; Peter, S; Willmann, M | 1 |
| Chaudhry, R; Choudhury, BP; Khatua, B; Mandal, C; Van Vleet, J | 1 |
| Bae, IK; Jeong, SH; Kim, YR; Lee, K; Suh, B; Wang, KK; Yong, D | 1 |
| Akers, KS; Hardy, SK; Murray, CK; Romano, DR; Sanchez, CJ; Wenke, JC; Woodbury, RL | 1 |
| Fukushima, S; Matsumoto, T; Nakamura, I; Sato, A; Tsukimori, A; Yamaguchi, T | 1 |
| Antonucci, E; Beumier, M; Cristallini, S; de Backer, D; Donadello, K; Jacobs, F; Roberts, JA; Rondelet, B; Scolletta, S; Taccone, FS; Vincent, JL | 1 |
| Bursle, E; Cotta, MO; Gowen, B; Lipman, J; McWhinney, B; Roberts, JA; Truloff, N; Ungerer, JP | 1 |
| Cuesta-Bernal, J; El-Delik, J; Frank, D; Göttig, S; Klingler, FM; Koenigs, A; Müller, HF; Pogoryelov, D; Pos, KM; Proschak, E; Sjuts, H; Wichelhaus, TA | 1 |
| Nordmann, P; Poirel, L; Potron, A | 1 |
| Bruno, JJ; Dee, BM; Qiao, W; Smith, ZR; Tajchman, SK; Tverdek, FP | 1 |
| Cies, JJ; Kuti, JL; Lapin, C; Muhlebach, MS; Neu, N; Nguyen, ST; Nicolau, DP; Novak, KJ; Pettit, RS; Saiman, L | 1 |
| Encinas, F; Fonseca, EL; Marin, MA; Vicente, AC | 1 |
| Buensuceso, RN; Burrows, LL; Lamers, RP; Nguyen, UT; Nguyen, Y | 1 |
| Ariza, J; Benavent, E; Cabo, X; Lora-Tamayo, J; Murillo, O; Pedrero, S; Ribera, A; Tubau, F | 1 |
| Armalytė, J; Kavaliauskas, P; Krasauskas, R; Labeikytė, D; Markuckas, A; Plančiūnienė, R; Povilonis, J; Sužiedėlienė, E | 1 |
| Fischer, DR; Namanny, H; Zobell, JT | 1 |
| Findlay, J; Hopkins, KL; Meunier, D; Mustafa, N; Parsons, H; Pike, R; Woodford, N; Wright, L | 1 |
| Burgess, DR; Burgess, DS; Martin, CA; Rutter, WC; Thompson, RZ | 1 |
| de Jonge, BL; Karlowsky, JA; Kazmierczak, KM; Nichols, WW; Sahm, DF | 1 |
| Bodenhofer, U; Bruchmann, S; Dötsch, A; Eckweiler, D; Häussler, S; Khaledi, A; Klawonn, F; Pohl, S; Preusse, M; Rainer, R; Schniederjans, M; Xia, B | 1 |
| Nicolau, DP; Sutherland, CA; Verastegui, JE | 1 |
| Adabi, M; Gholami, A; Majidpour, َ; Rasouli-Kouhi, S; Talebi-Taher, M | 1 |
| Borgia, G; Gentile, I; Maraolo, AE | 1 |
| Álvarez, C; Ardila, N; Ariza, B; Caro, MA; Gil, F; González, PF; Valderrama, SL | 1 |
| Abdel-Haq, N; Ang, JY; Nicolau, DP; Satlin, MJ; Thabit, AK; van Duin, D; Zhu, F | 1 |
| Al-Hasan, MN; Albrecht, H; Bookstaver, PB; Hammer, KL; Justo, JA; Kohn, J | 1 |
| Elphick, HE; Scott, A | 1 |
| Abe, T; Furuuchi, T; Ida, T; Inamura, S; Morinaka, A; Sakakibara, S; Sakamaki, Y; Takata, T; Takayama, Y; Tsujii, N; Tsutsumi, Y; Yamada, K | 1 |
| Choi, JY; Go, J; Kim, HJ; Lee, K; Lee, KM; Park, IH; Shin, JS; Yoon, SS | 1 |
| Galani, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Sarafis, P | 1 |
| Alves, AF; Cardoso, OM; Donato, AM; Leitão, R; Pena, A | 1 |
| Lima, AL; Oliveira, PR; Paula, AP; Zumiotti, AV | 1 |
| Cotterill, SL; Dawson, S; Faris, C; Kaufmann, ME; Livermore, DM; Tomas, Mdel M; Vardhan, MS; Woodford, N; Yarde, S; Zhang, J | 1 |
| Chuang, LY; Lee, S; Su, PW; Yang, CH; Yang, CS | 1 |
| Boutoille, D; Caillon, J; Jacqueline, C; Le Mabecque, V; Potel, G | 1 |
| Chen, YG; Li, LJ; Qu, TT; Tao, J; Wang, J; Yu, YS; Zhang, JL; Zhou, JY | 1 |
| Duljasz, W; Gniadkowski, M; Jebelean, C; Sitter, S; Wojna, A | 1 |
| Attrée, I; Ducruix, A; El Garch, F; Llanes, C; Muller, C; Phan, G; Plésiat, P; Vettoretti, L | 1 |
| Feizabadi, MM; Nikbin, VS; Shahcheraghi, F | 1 |
| Amicosante, G; Celenza, G; Galleni, M; Mercuri, PS; Pellegrini, C; Perilli, M; Sacchetti, E; Segatore, B; Volpe, R | 1 |
| Dal-Paz, K; Lima, AL; Oliveira, PR; Paula, AP; Rossi, F; Zumiotti, AV | 1 |
| Bou, G; Torres, E; Villanueva, R | 1 |
| Almela, M; López, J; López-Dupla, M; Marco, F; Martínez, JA; Mensa, J; Olona, M; Soriano, A; Vidal, F | 1 |
| Bettaieb, D; Bouallegue, O; Boujaafar, N; Mansour, W; Nordmann, P; Poirel, L | 1 |
| Citron, DM; Elgourt, T; Goldstein, EJ; Lu, S; Meibohm, AR; Peraino, V | 1 |
| He, C; Kazmierczak, BI; Lan, L; Murray, TS | 1 |
| Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Eagye, KJ; Nicolau, DP | 2 |
| Anderson, VL; Childs, R; Drusano, GL; Henning, SA; Holland, SM; Moriyama, B; Morris, JC; Walsh, TJ; Wilson, WH | 1 |
| Juan, C; Moyá, B; Oliver, A; Zamorano, L | 1 |
| Hu, ZQ; Zhao, WH | 1 |
| dos Santos, RP; Goldani, LZ; Jacoby, T | 1 |
| Chen, CY; Huang, YB; Liao, FF | 1 |
| Akhi, MT; Farajnia, S; Ghotaslou, R; Jazani, NH; Naghili, B; Nahaei, MR; Soroush, MH; Yousefi, S | 1 |
| Balasubramanian, D; Jayawardena, SR; Kong, KF; Leal, SM; Mathee, K; Sautter, RT | 1 |
| Amenomori, M; Fujita, H; Hara, A; Izumikawa, K; Kakeya, H; Kohno, S; Miyazaki, T; Nagayasu, T; Sakamoto, N; Seki, M; Tagawa, T; Takasaki, K; Tsuchiya, T; Yamamoto, Y; Yamasaki, N; Yanagihara, K | 1 |
| Bivas, A; Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
| Evdokimov, A; Han, S; Lacey, BM; Marr, ES; Miller, JR; Shanmugasundaram, V; Tomaras, AP; Zaniewski, RP | 1 |
| Ge, C; Jiang, Y; Li, L; Shen, P; Wei, Z; Yu, Y | 1 |
| Gastal, SL; Goldani, LZ; Gorniak Lovatto, C; Jacoby, T; Konkewicz, L; Kuplich, NM; Lisboa, T; Nagel, FM; Pires dos Santos, R; Pires Machado, D; Pires, MR | 1 |
| Koh, TH; Krishnan, P; Ong, DC; Syahidah, N; Tan, TY | 1 |
| Bordon, JM; Clark, RB; Karlowsky, JA; Master, RN; Ramirez, J | 1 |
| Beović, B; Cizman, M; Kreft, S; Seme, K | 1 |
| Antunes, AL; Barth, AL; Freitas, AL; Perez, LR | 1 |
| Cook, PP; Gooch, M; Rizzo, S | 1 |
| Bliziotis, IA; Falagas, ME; Michalopoulos, A; Petrosillo, N; Samonis, G | 1 |
| Carmeli, Y; Crank, CW; Goff, DA; Goldstein, EJ; Graber, CJ; Lima, AL; Nicolau, DP | 1 |
| Bhatt, J; Smyth, AR | 1 |
| Foley, SL; Han, J; Ji, C; Li, R; Lin, D; Qi, Y; Shen, J; Wang, Y; Wu, C | 1 |
| Ciofu, O; Høiby, N; Mandsberg, LF; Wang, H | 1 |
| Cheng, VC; Chow, KH; Ho, PL; Tse, H | 1 |
| Lister, PD; Wolter, DJ | 1 |
| Davies, TA; Flamm, RK; He, W; Kaniga, K; Lynch, AS | 1 |
| Cholley, P; Fournier, D; Jeannot, K; Muller, E; Plésiat, P; Robert-Nicoud, M; van der Mee-Marquet, N | 1 |
| Gion, M; Grandesso, S; Mazzuccato, S; Sapino, B; Solinas, M | 1 |
| Bebrone, C; Bennink, S; Bogaerts, P; Delbrück, H; Glupczynski, Y; Hoffmann, KM; Kupper, MB; Rezende de Castro, R | 1 |
| Antonelli, A; Bracco, S; Luzzaro, F; Maradei, S; Pollini, S; Rossolini, GM; Rumpianesi, F; Veggetti, A; Venturelli, C | 1 |
| Jain, M; Prickett, M | 1 |
| Crandon, JL; Hagihara, M; Nicolau, DP; Urban, CM | 1 |
| Cardoso, O; Duarte, A; Figueiredo, A; Leitão, R; Peixe, LV; Sousa, JC | 1 |
| Amicosante, G; Colì, A; Docquier, JD; Lombardi, G; Luzzaro, F; Perilli, M; Riccio, ML; Rossolini, GM; Toniolo, A | 1 |
| Li, C; Lister, PD; Nicolau, DP; Nightingale, CH; Quintiliani, R | 1 |
| Aubert, D; Girlich, D; Naas, T; Nagarajan, S; Nordmann, P | 1 |
| Bolmström, A; Chong, Y; Karlsson, A; Lee, K; Lim, YS; Qwärnström, A; Yong, D; Yum, JH | 1 |
| Baysallar, M; Doğanci, L; Kiliç, A; Küçükkaraaslan, A; Senses, Z | 1 |
| Evangelista, AT; Jones, ME; Karlowsky, JA; Sahm, DF; Thornsberry, C; Yee, YC | 1 |
| Coyle, EA; Melnick, DA; Schilling, AN; Tam, VH | 1 |
| Burgess, DS; Frei, CR | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP | 1 |
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Archambaud, M; Bonnet, E; Chabanon, G; Conil, JM; Cougot, P; Cristini, C; Decun, JF; Dubouix, A; Georges, B; Houin, G; Lauwers-Cancès, V; Marty, N; Mathe, O; Saivin, S; Seguin, T | 1 |
| Cai, P; Chang, D; Mi, Z; Wang, C | 1 |
| Rahal, JJ | 1 |
| Barth, AL; Fernandes, JF; Gaspareto, PB; Goldani, LZ; Gonçalves, AL; Moro, AL; Zavascki, AP | 1 |
| Falagas, ME; Horianopoulou, M; Kanellopoulou, M; Lambropoulos, S; Legakis, NJ; Tsakris, A | 1 |
| Drusano, GL; Lodise, TP; Lomaestro, B | 1 |
| DeRyke, CA; Kuti, JL; Nicolau, DP | 1 |
| Falagas, ME; Manta, KG; Siempos, II; Vardakas, KZ | 1 |
| Markova, B; Marteva-Proevska, Y; Mitov, I; Ouzounova-Raykova, V; Strateva, T; Todorova, A | 1 |
| Bajolet, O; Berthelot, P; Bingen, E; Couetdic, G; Favre, R; Grattard, F; Hocquet, D; Husson, MO; Jeannot, K; Mariani-Kurkdjian, P; Marty, N; Plésiat, P; Roussel-Delvallez, M | 1 |
| Bhat, S; Capitano, B; Fujitani, S; Linden, PK; Paterson, DL; Potoski, BA; Shutt, K | 1 |
| Cuzon, G; Lartigue, MF; Naas, T; Nordmann, P; Quinn, JP; Villegas, MV | 1 |
| Giakkoupi, P; Kalapothaki, V; Polemis, M; Tzouvelekis, LS; Vatopoulos, AC; Vourli, S | 1 |
| Benoit, D; Blot, S; Decruyenaere, J; Depuydt, P | 1 |
| Hirakata, Y; Kamihira, S; Kohno, S; Matsuda, J; Morinaga, Y; Motoshima, M; Sugahara, K; Yamada, Y; Yamamoto, K; Yanagihara, K | 1 |
| Limansky, AS; Marchiaro, P; Mussi, MA; Pasteran, F; Tomatis, PE; Viale, AM; Vila, AJ | 1 |
| Anstead, MI; Hayes, D; Kanga, JF; Kuhn, RJ | 1 |
| André, C; Arpin, C; Brochet, JP; Coulange, L; Dubois, V; Dupart, V; Dutilh, B; Fischer, I; Grobost, F; Jullin, J; Lagrange, I; Larribet, G; Noury, P; Quentin, C; Scavelli, A | 1 |
| King, A; Phillips, I; Shannon, K | 1 |
| Slack, MP | 1 |
| Neu, HC; Prince, AS | 1 |
| Fugono, T; Imada, A; Kondo, M; Nakao, M; Nishi, T; Tsuchiya, K | 1 |
| Baltch, AL; Smith, RP; Wu, DH | 1 |
| Kitaura, K; Mineura, K; Nakamizo, N; Ohmori, M; Saito, A; Shiba, K; Ueda, Y | 1 |
| Lerner, AM; Reyes, MP; Smith, F | 1 |
| Bergogne-Berezin, E; Berthelot, G; Even, P; Gibert, C; Kafe, H; Pierre, J; Safran, D; Stern, M | 1 |
| Mirelman, D; Nuchamowitz, Y; Rubinstein, E | 1 |
| Homma, JY; Iki, Y; Inatomi, K; Kasai, T; Kunii, O; Mashimo, K; Nishimura, Y; Shimada, K; Takigami, T; Tanimoto, H | 1 |
| Parker, CW; Shatz, GS; Sullivan, TJ; Wedner, HJ; Yecies, LD | 1 |
| Rolinson, GN | 1 |
| Corkill, JE; Deveney, J; Hart, CA; Heaf, D; Pratt, J; Shears, P; Smyth, A | 1 |
| Cahen, P; Coustère, C; de Blic, J; Delacourt, C; Gaillard, JL; Le Bourgeois, M; Lenoir, G; Scheinmann, P; Silly, C | 1 |
| Ciofu, O; Giwercman, B; Høiby, N; Pedersen, SS; Pressler, T; Walter-Rasmussen, J | 1 |
| Pleasants, RA; Samuelson, WM; Walker, TR | 1 |
| Hurley, JC | 1 |
| Cheng, K; Denning, N; Doherty, C; Govan, JR; Hart, CA; Heaf, DP; Smyth, RL; van Saene, H; Winstanley, C | 1 |
| Ciofu, O; Giwercman, B; Høiby, N; Pedersen, SS; Petersen, TD; Pressler, T | 1 |
| Brownlee, KG; Conway, SP; Denton, M; Littlewood, JM; Todd, NJ | 1 |
| Pedersen, HB; Rosborg, J | 1 |
| Amicosante, G; Bonfiglio, G; Franchino, L; Laksai, Y; Nicoletti, G | 1 |
| Cavallo, J; Gidenne, S; Hernandez, E; Ramisse, F; van Delden, C | 1 |
| Domenig, C; Klepetko, W; Kozek, S; Spiss, C; Steininger, R; Thalhammer, F; Traunmüller, F; Wisser, W | 1 |
| Andre, C; Arpin, C; Dubois, V; Frigo, C; Melon, B; Melon, M; Quentin, C | 1 |
| De Champs, C; Nordmann, P; Poirel, L; Weldhagen, GF | 1 |
| Allouch, P; Chardon, H; Chiche, D; Didion, J; Jurin, F; Pina, P; Rio, Y | 1 |
| Beach, ML; Biedenbach, DJ; Jones, RN; Kirby, JT; Pfaller, MA | 1 |
| Fukada, S; Kojo, H; Mine, Y; Nishida, M; Nonoyama, S | 1 |
| Ullmann, U | 1 |
| Giwercman, B; Høiby, N; Lambert, PA; Meyer, C; Reinert, C | 1 |
| Friedman, BA; Pierson, CL | 1 |
| Craig, WA; Ebert, S; Fantin, B; Leggett, JE | 1 |
| Esteva, C; Hermida, M; Reig, R; Roy, C; Tirado, M; Vidal, R | 1 |
| Cereda, PM; Debiaggi, M; Landini, P; Pagani, L; Romero, E; Tenni, R | 1 |
| Okachi, R; Sato, K; Yamashita, K | 1 |
| Demko, GM | 1 |
| Cereda, PM; Debiaggi, M; Pagani, L; Scarabelli, M | 1 |
| Dzierzanowska, D; Patzer, J | 1 |
| Bercion, R; Buisson, Y; Hugard, L; Mauclère, P; Schill, H | 1 |
| Henry, DA; Smith, JA | 1 |
| DeJace, P; Klastersky, J | 1 |
| Beaufils, F; Bingen, E; Guihaire, E; Lambert-Zechovsky, N; Mancy, C; Mercier, JC | 1 |
| Aoki, B; Kojima, K; Kuroki, T; Matsumoto, M; Nehashi, T; Ohi, N | 1 |
| Lerner, SA; Quinn, JP | 1 |
| Bryan, LE; Godfrey, AJ; Schollardt, T | 1 |
| Maki, DG; Nichols, L | 1 |
22 review(s) available for beta-lactams and Infections, Pseudomonas
| Article | Year |
|---|---|
Comparative efficacy and safety of antipseudomonal β-lactams for pediatric febrile neutropenia: A systematic review and Bayesian network meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftazidime; Child; Drug Therapy, Combination; Febrile Neutropenia; Female; Humans; Imipenem; Male; Meropenem; Network Meta-Analysis; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Therapy, Combination; Humans; Pneumonia, Ventilator-Associated; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Treatment Outcome | 2022 |
Present and future of resistance in Pseudomonas aeruginosa: implications for treatment.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review.
Topics: Anti-Bacterial Agents; beta-Lactams; Humans; Infusions, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections | 2019 |
Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; beta-Lactams; Child; Cohort Studies; Drug Therapy, Combination; Humans; Incidence; Intensive Care Units; Network Meta-Analysis; Pseudomonas Infections; Vancomycin | 2020 |
Current choices of antibiotic treatment for Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactamase Inhibitors; beta-Lactams; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Phage Therapy; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cephalosporins; Child; Cystic Fibrosis; Drug Therapy, Combination; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections | 2021 |
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Topics: Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Body Mass Index; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Injections, Intravenous; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin; Vital Capacity; Young Adult | 2017 |
Head-to-head trials of antibiotics for bronchiectasis.
Topics: Adult; Aminoglycosides; Amoxicillin; Anti-Bacterial Agents; beta-Lactams; Bronchiectasis; Child; Fluoroquinolones; Forced Expiratory Volume; Humans; Polymyxins; Pseudomonas Infections; Randomized Controlled Trials as Topic | 2018 |
β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Drug Therapy, Combination; Fluoroquinolones; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections | 2016 |
Beta-lactamases identified in clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fever; Humans; Imipenem; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Thienamycins | 2010 |
Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Bacterial; Ertapenem; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Humans; Injections, Intravenous; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin; Young Adult | 2012 |
Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Biofilms; Chronic Disease; Cystic Fibrosis; Humans; Lung; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Selection, Genetic | 2012 |
Mechanisms of β-lactam resistance among Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.
Topics: Acinetobacter; Acinetobacter Infections; Aminoglycosides; beta-Lactams; Clinical Trials as Topic; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones | 2006 |
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aminoglycosides; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Multiple; Drug Therapy, Combination; Fluoroquinolones; Humans; Immunocompetence; Intensive Care Units; Meropenem; Pneumonia, Bacterial; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiration, Artificial; Survival Rate; Thienamycins; Treatment Outcome | 2007 |
Antipseudomonal beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoperazone; Cefotaxime; Cefsulodin; Ceftazidime; Ceftriaxone; Cephalosporins; Cephamycins; Drug Stability; Lactams; Moxalactam; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1981 |
Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cellulitis; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Neoplasms; Neutropenia; Pneumonia; Pseudomonas Infections; Sepsis; Urinary Tract Infections | 1986 |
3 trial(s) available for beta-lactams and Infections, Pseudomonas
| Article | Year |
|---|---|
Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactams; Drug Administration Routes; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas Infections; Research Design; Treatment Outcome | 2017 |
Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.
Topics: Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Infant; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Respiratory Tract Infections; Serum Bactericidal Test; Sputum; Treatment Outcome | 1995 |
Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cellulitis; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Neoplasms; Neutropenia; Pneumonia; Pseudomonas Infections; Sepsis; Urinary Tract Infections | 1986 |
170 other study(ies) available for beta-lactams and Infections, Pseudomonas
| Article | Year |
|---|---|
Alcaligenes faecalis metallo-β-lactamase in extensively drug-resistant Pseudomonas aeruginosa isolates.
Topics: Alcaligenes faecalis; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Humans; Microbial Sensitivity Tests; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Antipseudomonal treatment decisions during CF exacerbation management.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Cystic Fibrosis; Female; Fluoroquinolones; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2022 |
Advanced transcriptomic analysis reveals the role of efflux pumps and media composition in antibiotic responses of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Biofilms; Gene Expression Profiling; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
Positive Bacterial Culture Results at a Dermatologic Surgery Center: A Single-Site Retrospective Review.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; beta-Lactam Resistance; beta-Lactams; Dermatologic Surgical Procedures; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Surgical Wound Infection | 2020 |
Antibiotic treatment adequacy and death among patients with Pseudomonas aeruginosa airway infection.
Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; beta-Lactams; Denmark; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Prognosis; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2019 |
Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill.
Topics: Academic Medical Centers; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Critical Illness; Drug Resistance, Bacterial; Female; Humans; Male; Middle Aged; Missouri; Pseudomonas; Pseudomonas Infections | 2020 |
Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Bone Diseases, Infectious; Ciprofloxacin; Cohort Studies; Colistin; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Female; Humans; Infusions, Intravenous; Joint Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
Analysis of Metallo-β-lactamases, oprD Mutation, and Multidrug Resistance of β-lactam Antibiotic-Resistant Strains of Pseudomonas aeruginosa Isolated from Southern China.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; China; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
Performance of Antipseudomonal β-Lactams on the Accelerate PhenoTest BC Kit against a Collection of Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
Antibiotic resistance heterogeneity and LasR diversity within Pseudomonas aeruginosa populations from pneumonia in intensive care unit patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Bronchoalveolar Lavage; Ceftazidime; DNA, Bacterial; Drug Resistance, Bacterial; Genetic Variation; Humans; Imipenem; Intensive Care Units; Microbial Sensitivity Tests; Mutation; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Trans-Activators | 2021 |
Development of potent antipseudomonal β-lactams by means of polycarboxylation of aminopenicillins.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Humans; Mice; Microbial Sensitivity Tests; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections | 2021 |
Increased risk of death with recurrent Pseudomonas aeruginosa bacteremia.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Retrospective Studies; Risk Factors; Tertiary Care Centers; Young Adult | 2017 |
Patterns of antimicrobial resistance in intensive care unit patients: a study in Vietnam.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Female; Humans; Imipenem; Intensive Care Units; Klebsiella; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Vietnam | 2017 |
Collateral sensitivity between aminoglycosides and beta-lactam antibiotics depends on active proton pumps.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactams; Burns; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Genes, Bacterial; Genes, MDR; Gentamicins; Humans; Imipenem; Iran; Membrane Transport Proteins; Microbial Sensitivity Tests; Polymerase Chain Reaction; Proton Pumps; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Ciprofloxacin; Cohort Studies; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Taiwan; Treatment Outcome | 2018 |
Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case-case-control study.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Case-Control Studies; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors | 2018 |
Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections.
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Cohort Studies; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Switzerland | 2018 |
Reproducibility between two readout methods of a commercial broth microdilution assay for Pseudomonas aeruginosa isolates from patients with Cystic Fibrosis.
Topics: Anti-Bacterial Agents; beta-Lactams; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Reproducibility of Results | 2019 |
Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.
Topics: Adaptation, Biological; Adult; Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cystic Fibrosis; Female; Humans; Longitudinal Studies; Male; Microbial Sensitivity Tests; Mutation, Missense; Penicillin-Binding Proteins; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; Sputum | 2019 |
Dual β-lactam combination therapy for multi-drug resistant Pseudomonas aeruginosa infection: enhanced efficacy in vivo and comparison with monotherapies of penicillin-binding protein inhibition.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Drug Interactions; Drug Resistance, Multiple; Humans; Lepidoptera; Penicillin-Binding Proteins; Pseudomonas aeruginosa; Pseudomonas Infections; Survival Analysis | 2019 |
In Vivo Validation of Peptidoglycan Recycling as a Target to Disable AmpC-Mediated Resistance and Reduce Virulence Enhancing the Cell-Wall-Targeting Immunity.
Topics: Animals; Bacteremia; Bacterial Load; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Ceftazidime; Cell Wall; Disease Models, Animal; Female; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Peptidoglycan; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Survival Analysis; Treatment Outcome; Virulence | 2019 |
Pseudomonas aeruginosa populations in the cystic fibrosis lung lose susceptibility to newly applied β-lactams within 3 days.
Topics: Adult; Anti-Bacterial Agents; Bacterial Load; beta-Lactam Resistance; beta-Lactams; Cluster Analysis; Cohort Studies; Cystic Fibrosis; DNA, Bacterial; DNA, Ribosomal; Female; Humans; Lung; Male; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Young Adult | 2019 |
Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Child; Child, Preschool; Cystic Fibrosis; Female; France; Gene Expression Profiling; Genes, Bacterial; Genetic Variation; Genotype; Hospitals, University; Humans; Infant; Isoelectric Focusing; Male; Microbial Sensitivity Tests; Middle Aged; Minisatellite Repeats; Molecular Typing; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Young Adult | 2013 |
Outbreak of metallo-β-lactamase VIM-2-positive strains of Pseudomonas aeruginosa in the Ivory Coast.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cote d'Ivoire; Disease Outbreaks; DNA, Bacterial; Gene Order; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2013 |
Can changes in renal function predict variations in β-lactam concentrations in septic patients?
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Chromatography, High Pressure Liquid; Creatinine; Female; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Pseudomonas Infections; Sepsis; Serum | 2013 |
Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Case-Control Studies; Drug Resistance, Bacterial; Ertapenem; Humans; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
A subclass B3 metallo-β-lactamase found in Pseudomonas alcaligenes.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cluster Analysis; Cross Infection; Genotype; Humans; Microbial Sensitivity Tests; Pseudomonas alcaligenes; Pseudomonas Infections; Sequence Analysis, DNA | 2014 |
Evaluation of phenotypic detection methods for metallo-β-lactamases (MBLs) in clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity | 2014 |
Sialylation of outer membrane porin protein D: a mechanistic basis of antibiotic uptake in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactams; Humans; Polysaccharides; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Sialic Acids | 2014 |
Molecular epidemiology of Pseudomonas aeruginosa clinical isolates from Korea producing β-lactamases with extended-spectrum activity.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Drug Resistance, Bacterial; Genotype; Hospitals, University; Humans; Molecular Epidemiology; Multilocus Sequence Typing; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Republic of Korea | 2014 |
D-amino acids enhance the activity of antimicrobials against biofilms of clinical wound isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Amino Acids; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Biofilms; Clindamycin; Drug Synergism; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Surface-Active Agents; Vancomycin; Wounds and Injuries | 2014 |
New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Tokyo | 2015 |
β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Case-Control Studies; Extracorporeal Membrane Oxygenation; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Sepsis; Serum; Thienamycins; Treatment Outcome | 2015 |
Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Bacterial; Female; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Thienamycins | 2015 |
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Crystallography, X-Ray; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Models, Molecular; Pseudomonas aeruginosa; Pseudomonas Infections; Sulfhydryl Compounds | 2015 |
Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population.
Topics: Administration, Intravenous; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Medical Oncology; Microbial Sensitivity Tests; Middle Aged; Neoplasms; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2016 |
Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Child; Cystic Fibrosis; Female; Humans; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
Full characterization of the integrative and conjugative element carrying the metallo-β-lactamase bla SPM-1 and bicyclomycin bcr1 resistance genes found in the pandemic Pseudomonas aeruginosa clone SP/ST277.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Brazil; Bridged Bicyclo Compounds, Heterocyclic; Conjugation, Genetic; Drug Resistance, Bacterial; Genome, Bacterial; Genotype; Interspersed Repetitive Sequences; Molecular Typing; Pandemics; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2015 |
Loss of membrane-bound lytic transglycosylases increases outer membrane permeability and β-lactam sensitivity in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Biological Transport; Cell Membrane; Glycosyltransferases; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Colistin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Osteoarthritis; Prospective Studies; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Treatment Outcome | 2015 |
Purification and characterization of a new β-lactamase OXA-205 from Pseudomonas aeruginosa.
Topics: Amino Acid Sequence; beta-Lactamases; beta-Lactams; Chromatography, Gel; Chromatography, Ion Exchange; Cloning, Molecular; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Gene Expression; Humans; Hydrolysis; Integrons; Isoelectric Focusing; Isoelectric Point; Kinetics; Models, Molecular; Molecular Sequence Data; Molecular Weight; Protein Conformation; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Alignment; Substrate Specificity | 2015 |
Follow-up survey of the utilization of anti-pseudomonal beta-lactam antibiotics at U.S. cystic fibrosis centers.
Topics: Anti-Bacterial Agents; beta-Lactams; Cystic Fibrosis; Follow-Up Studies; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Surveys and Questionnaires | 2016 |
SPM-1 metallo-β-lactamase-producing Pseudomonas aeruginosa ST277 in the UK.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; United Kingdom | 2016 |
Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Cystic Fibrosis; Drug Administration Routes; Female; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Models, Theoretical; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 2016 |
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).
Topics: Africa; Amikacin; Anti-Bacterial Agents; Asia; Azabicyclo Compounds; beta-Lactams; Ceftazidime; Colistin; Drug Combinations; Humans; Latin America; Meropenem; Microbial Sensitivity Tests; Middle East; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2016 |
Transcriptome Profiling of Antimicrobial Resistance in Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gene Expression Profiling; High-Throughput Nucleotide Sequencing; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Transcriptome | 2016 |
In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2016 |
Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Biological Transport, Active; Burns; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Iran; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Humans; Intraabdominal Infections; Penicillanic Acid; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2016 |
Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Topics: Bacteremia; beta-Lactams; Carbapenems; Case-Control Studies; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Hospitals; Humans; Meropenem; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Thienamycins | 2016 |
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Differential effect of prior β-lactams and fluoroquinolones on risk of bloodstream infections secondary to Pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Case-Control Studies; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Assessment | 2017 |
In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Humans; Lactams; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
A Genetic Screen Reveals Novel Targets to Render
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Caenorhabditis elegans; Cell Wall; Disease Models, Animal; DNA Transposable Elements; Gene Knockout Techniques; Genetic Complementation Test; Genetic Testing; Mice, Inbred C57BL; Microbial Viability; Muramidase; Mutagenesis, Insertional; Pseudomonas aeruginosa; Pseudomonas Infections; Vancomycin; Virulence | 2017 |
In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Ciprofloxacin; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Microbial Viability; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Time Factors | 2008 |
Detection of Pseudomonas aeruginosa producing metallo-beta-lactamase VIM-2 in a central hospital from Portugal.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cross Infection; Hospitals; Humans; Microbial Sensitivity Tests; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Influence of ertapenem administration on the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactams; Brazil; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Cluster Analysis; Disease Outbreaks; DNA Fingerprinting; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Genotype; Hospitals; Humans; India; Microbial Sensitivity Tests; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; Serotyping; United Kingdom | 2008 |
Genotype and antibiotic susceptibility patterns of drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates in Taiwan.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; DNA, Bacterial; Drug Resistance, Bacterial; Genotype; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Random Amplified Polymorphic DNA Technique; Taiwan | 2008 |
In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactams; Colony Count, Microbial; Endocarditis, Bacterial; Female; Humans; Membrane Transport Proteins; Models, Theoretical; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 2009 |
Evaluation of phenotypic tests for detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa strains in China.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; China; DNA, Bacterial; Humans; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; RNA, Bacterial; RNA, Messenger | 2009 |
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
Topics: Austria; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2009 |
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactams; Cystic Fibrosis; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 2009 |
Prevalence of ESBLs genes among multidrug-resistant isolates of Pseudomonas aeruginosa isolated from patients in Tehran.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; DNA Primers; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Iran; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Identification of bla(IMP-22) in Pseudomonas spp. in urban wastewater and nosocomial environments: biochemical characterization of a new IMP metallo-enzyme variant and its genetic location.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; beta-Lactams; Cross Infection; DNA, Bacterial; Enzyme Inhibitors; Gene Order; Humans; Inhibitory Concentration 50; Isoelectric Point; Italy; Kinetics; Molecular Sequence Data; Molecular Weight; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pseudomonas Infections; Sequence Analysis, DNA; Water Microbiology | 2009 |
The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
Topics: Academic Medical Centers; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Brazil; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Ertapenem; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Automation; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Genetic Predisposition to Disease; Humans; Imipenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; beta-Lactams; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2009 |
Metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates in Tunisia.
Topics: Aged; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Cluster Analysis; DNA Fingerprinting; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Genotype; Humans; Integrons; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tunisia | 2009 |
Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactams; Ertapenem; Formularies, Hospital as Topic; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sulbactam | 2009 |
Pseudomonas aeruginosa OspR is an oxidative stress sensing regulator that affects pigment production, antibiotic resistance and dissemination during infection.
Topics: Amino Acid Substitution; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Female; Gene Deletion; Gene Expression Regulation, Bacterial; Glutathione Peroxidase; Hydrogen Peroxide; Mice; Mice, Inbred C57BL; Models, Biological; Mutagenesis, Site-Directed; Oxidative Stress; Pigments, Biological; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Repressor Proteins; Signal Transduction; Stress, Physiological; Tyrosine; Virulence | 2010 |
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Resistance, Bacterial; Ertapenem; Hospitals; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; Practice Patterns, Physicians'; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2010 |
High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactams; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Female; Humans; Immunocompromised Host; Infusions, Intravenous; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2010 |
Differential beta-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Gene Deletion; Humans; Microbial Sensitivity Tests; N-Acetylmuramoyl-L-alanine Amidase; Penicillin-Binding Proteins; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance?
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ertapenem; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 2010 |
Decrease in serum valproic acid levels during treatment with ertapenem.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cellulitis; Drug Antagonism; Ertapenem; Female; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Seizures; Staphylococcal Infections; Staphylococcus epidermidis; Valproic Acid | 2010 |
Detection of metallo-β-lactamase-encoding genes among clinical isolates of Pseudomonas aeruginosa in northwest of Iran.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; DNA, Bacterial; Humans; Integrons; Iran; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Co-regulation of {beta}-lactam resistance, alginate production and quorum sensing in Pseudomonas aeruginosa.
Topics: Alginates; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Caenorhabditis elegans; Disease Models, Animal; Drug Resistance, Bacterial; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Glucuronic Acid; Hexuronic Acids; Promoter Regions, Genetic; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Sigma Factor; Virulence; Virulence Factors | 2011 |
Importance of controlling drug-resistant Pseudomonas aeruginosa infection: experience from lung transplantation in a cystic fibrosis case.
Topics: Aminoglycosides; beta-Lactam Resistance; beta-Lactams; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Lung Transplantation; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2010 |
Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa.
Topics: Amino Acids, Aromatic; Anti-Bacterial Agents; beta-Lactams; Cross Infection; Crystallography, X-Ray; Humans; Models, Molecular; Penicillin-Binding Proteins; Protein Structure, Tertiary; Pseudomonas aeruginosa; Pseudomonas Infections; Siderophores | 2010 |
Identification of KPC-2-producing Pseudomonas aeruginosa isolates in China.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carrier State; China; Feces; Humans; Intensive Care Units; Microbial Sensitivity Tests; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Drug Utilization; Ertapenem; Hospitals; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Carbapenems; Cross Infection; Ertapenem; Hand Disinfection; Hospitals, University; Humans; Incidence; Pseudomonas aeruginosa; Pseudomonas Infections; Regression Analysis | 2011 |
Rapid detection of the blaNDM-1 gene by real-time PCR.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; DNA Primers; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Time Factors | 2011 |
Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Carbapenems; Cephalosporins; Cross Infection; Databases, Factual; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2011 |
Does ertepenem alter the susceptibility of Pseudomonas aeruginosa to carbapenems?
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Drug Interactions; Ertapenem; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
When the resistance gets clingy: Pseudomonas aeruginosa harboring metallo-β-lactamase gene shows high ability to produce biofilm.
Topics: beta-Lactam Resistance; beta-Lactams; Biofilms; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 2012 |
Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Ertapenem; Fluoroquinolones; Formularies, Hospital as Topic; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; North Carolina; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2011 |
Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Cohort Studies; Drug Therapy, Combination; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Retrospective Studies; Treatment Outcome | 2011 |
Characterization of antimicrobial resistance of Pseudomonas aeruginosa isolated from canine infections.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; beta-Lactams; China; DNA, Bacterial; Dog Diseases; Dogs; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2012 |
Effect of applying the new Clinical and Laboratory Standards Institute ticarcillin/clavulanic acid, piperacillin, piperacillin/tazobactam and imipenem susceptibility breakpoints for Pseudomonas aeruginosa in Hong Kong.
Topics: Anti-Bacterial Agents; beta-Lactams; Hong Kong; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Colistin; Drug Synergism; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Spread of the bla(IMP-13) gene in French Pseudomonas aeruginosa through sequence types ST621, ST308 and ST111.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; DNA, Bacterial; Genotype; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Molecular Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2012 |
Comparison of different methods for determining beta-lactam susceptibility in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactams; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
GES-18, a new carbapenem-hydrolyzing GES-Type β-lactamase from Pseudomonas aeruginosa that contains Ile80 and Ser170 residues.
Topics: Aged, 80 and over; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Catalytic Domain; Cloning, Molecular; Crystallography, X-Ray; Escherichia coli; Humans; Kinetics; Male; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Respiratory Tract Infections | 2013 |
Acquisition of plasmid-borne blaIMP-19 gene by a VIM-1-positive Pseudomonas aeruginosa of the sequence type 235 epidemic lineage.
Topics: Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; DNA, Bacterial; Female; Gene Order; Genotype; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2013 |
Efficacy of β-lactams as single agents for treating severe pulmonary exacerbations during pregnancy in cystic fibrosis.
Topics: Administration, Intravenous; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Contraindications; Cystic Fibrosis; Disease Progression; Female; Humans; Pregnancy; Pregnancy Complications, Infectious; Pseudomonas Infections; Treatment Outcome | 2012 |
KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Doripenem; Ertapenem; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Metallo-beta-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; DNA, Bacterial; Electrophoresis, Polyacrylamide Gel; Humans; Microbial Sensitivity Tests; Portugal; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction | 2002 |
Nosocomial infections caused by multidrug-resistant isolates of pseudomonas putida producing VIM-1 metallo-beta-lactamase.
Topics: Aged; beta-Lactamases; beta-Lactams; Carbapenems; Cross Infection; Drug Resistance, Multiple, Bacterial; Humans; Integrons; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Pseudomonas Infections; Pseudomonas putida; Urinary Tract Infections | 2002 |
Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Colony Count, Microbial; Drug Synergism; Enzyme Induction; Enzyme Inhibitors; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 2004 |
Functional and structural characterization of the genetic environment of an extended-spectrum beta-lactamase blaVEB gene from a Pseudomonas aeruginosa isolate obtained in India.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; beta-Lactams; Cloning, Molecular; Conjugation, Genetic; Culture Media; DNA, Bacterial; Drug Resistance, Bacterial; Electroporation; India; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2004 |
Evaluation of Etest MBL for detection of blaIMP-1 and blaVIM-2 allele-positive clinical isolates of Pseudomonas spp. and Acinetobacter spp.
Topics: Acinetobacter; Acinetobacter Infections; Alleles; beta-Lactamases; beta-Lactams; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa; Pseudomonas Infections; Pseudomonas putida; Sensitivity and Specificity | 2005 |
[Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Intensive Care Units; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2004 |
Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies.
Topics: beta-Lactams; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2005 |
Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cross Infection; Electrophoresis, Polyacrylamide Gel; Humans; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Pseudomonas Infections | 2005 |
Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactams; Enterobacteriaceae; Enterobacteriaceae Infections; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 2005 |
Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Topics: Anti-Bacterial Agents; beta-Lactams; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2005 |
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents.
Topics: Bacteriological Techniques; beta-Lactam Resistance; beta-Lactams; Humans; Microbial Sensitivity Tests; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2006 |
Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units.
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Female; Follow-Up Studies; Humans; Incidence; Intensive Care Units; Male; Middle Aged; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors | 2006 |
A Pseudomonas aeruginosa isolate producing the GES-5 extended-spectrum beta-lactamase.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; China; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; Sequence Homology; Wound Infection | 2006 |
Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiary-care teaching hospitals.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Case-Control Studies; Cross Infection; Female; Fluoroquinolones; Hospitals, Teaching; Humans; Incidence; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors | 2006 |
Frequency and predictors of colonization of the respiratory tract by VIM-2-producing Pseudomonas aeruginosa in patients of a newly established intensive care unit.
Topics: Acute Disease; beta-Lactamases; beta-Lactams; Bronchi; Carbapenems; Carrier State; Cross Infection; Female; Genes, Bacterial; Gram-Negative Bacteria; Greece; Hospitals, General; Humans; Intensive Care Units; Male; Middle Aged; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Time Factors; Trachea; Urban Population | 2006 |
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; beta-Lactams; Cohort Studies; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Retrospective Studies | 2007 |
Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
Topics: Acinetobacter baumannii; Acinetobacter Infections; beta-Lactams; Cross Infection; Escherichia coli; Fluoroquinolones; Gram-Negative Bacteria; Humans; Intensive Care Units; Klebsiella; Klebsiella Infections; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2007 |
Widespread detection of VEB-1-type extended-spectrum beta-lactamases among nosocomial ceftazidime-resistant Pseudomonas aeruginosa isolates in Sofia, Bulgaria.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Bulgaria; Cephalosporin Resistance; Cross Infection; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactams; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Genotype; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Topics: Algorithms; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Intensive Care Units; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors | 2007 |
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
Topics: Base Sequence; beta-Lactamases; beta-Lactams; Cloning, Molecular; Colombia; DNA Transposable Elements; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; United States | 2008 |
Supplementation of growth media with Zn2+ facilitates detection of VIM-2-producing Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; beta-Lactamases; beta-Lactams; Culture Media; Edetic Acid; Greece; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Zinc | 2008 |
Improving the adequacy of empirical beta-lactam therapy for Pseudomonas aeruginosa ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Humans; Intensive Care Units; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Quantitative detection of metallo-beta-lactamase of blaIMP-cluster-producing Pseudomonas aeruginosa by real-time polymerase chain reaction with melting curve analysis for rapid diagnosis and treatment of nosocomial infection.
Topics: beta-Lactamases; beta-Lactams; Cross Infection; DNA Gyrase; Humans; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity | 2008 |
Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain.
Topics: beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Binding Sites; Escherichia coli; Humans; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure.
Topics: Aminoglycosides; Anti-Bacterial Agents; Area Under Curve; beta-Lactams; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infant; Infusions, Intravenous; Inpatients; Outpatients; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Failure; Treatment Outcome | 2008 |
Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).
Topics: Acetyltransferases; Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Child; Child, Preschool; Community Health Centers; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Female; France; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Middle Aged; Nucleotidyltransferases; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2008 |
Development of resistance to beta-lactam antibiotics during therapy of Pseudomonas aeruginosa infections.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Drug Resistance, Microbial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 1982 |
Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbenicillin; Cefoperazone; Cefotaxime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Imipenem; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1981 |
Relevance of in vitro antibacterial activities and pharmacokinetic properties of antipseudomonal beta-lactam antibiotics to their therapeutic effects on urinary tract infection caused by Pseudomonas aeruginosa P 9 in mice.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Female; Kidney; Kinetics; Mice; Microbial Sensitivity Tests; Nephelometry and Turbidimetry; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections | 1984 |
In vitro comparison of Pseudomonas aeruginosa isolates with various susceptibilities to aminoglycosides and ten beta-lactam antibiotics.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 1984 |
Synergistic activity of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa in vitro and in vivo.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; beta-Lactams; Drug Synergism; Male; Mice; Mice, Inbred Strains; Pseudomonas aeruginosa; Pseudomonas Infections | 1984 |
Studies of in vitro synergy between several beta-lactam and aminoglycoside antibiotics against endocarditis strains of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Drug Synergism; Endocarditis, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pseudomonas Infections | 1984 |
[Bronchial diffusion of new anti-pseudomonal beta-lactams. Clinical significance].
Topics: Anti-Bacterial Agents; beta-Lactams; Bronchi; Humans; Kinetics; Pseudomonas Infections | 1984 |
Insensitivity of peptidoglycan biosynthetic reactions to beta-lactam antibiotics in a clinical isolate of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cell Wall; Drug Resistance, Microbial; Humans; Peptidoglycan; Protein Binding; Pseudomonas aeruginosa; Pseudomonas Infections; Species Specificity | 1981 |
Combination therapy using 9,3"-di-O-acetyl-midecamycin with beta-lactam antibiotics against Pseudomonas aeruginosa infection.
Topics: Adult; Agammaglobulinemia; Aged; Anti-Bacterial Agents; beta-Lactams; Bronchiectasis; Bronchitis; Drug Therapy, Combination; Female; Humans; Leucomycins; Male; Middle Aged; Miocamycin; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Emphysema; Urinary Bladder, Neurogenic | 1981 |
Desensitization of patients allergic to penicillin using orally administered beta-lactam antibiotics.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Carbenicillin; Desensitization, Immunologic; Drug Hypersensitivity; Endocarditis, Bacterial; Female; Humans; Male; Middle Aged; Oxacillin; Penicillins; Pneumonia; Pseudomonas Infections; Staphylococcal Infections | 1982 |
Basis and results of therapy with Beta-lactam antibiotics in experimental infections.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Drug Administration Schedule; Mice; Penicillins; Pseudomonas Infections; Staphylococcal Infections; Streptococcal Infections | 1980 |
Effect of pH and CO2 on in vitro susceptibility of Pseudomonas cepacia to beta-lactams.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; beta-Lactamase Inhibitors; beta-Lactams; Burkholderia cepacia; Carbon Dioxide; Child; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Microbial Sensitivity Tests; Opportunistic Infections; Pseudomonas Infections; Sputum | 1994 |
Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams.
Topics: Adolescent; Adult; Antibodies, Bacterial; beta-Lactamases; beta-Lactams; Biomarkers; Child; Child, Preschool; Chromosomes, Bacterial; Cross-Sectional Studies; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Infant; Longitudinal Studies; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Reproducibility of Results; Sensitivity and Specificity | 1995 |
Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Cystic Fibrosis; Drug Hypersensitivity; Female; Fever; Humans; Incidence; Male; Pseudomonas Infections; Retrospective Studies; Time Factors | 1994 |
Beta-lactam antibiotic-induced release of free lipopolysaccharide.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; In Vitro Techniques; Lipopolysaccharides; Mice; Pseudomonas aeruginosa; Pseudomonas Infections | 1993 |
Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Cross Infection; Cystic Fibrosis; DNA Fingerprinting; Drug Resistance, Microbial; Genotype; Humans; Infant; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sputum | 1996 |
Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blotting, Western; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Densitometry; Drug Resistance, Microbial; Humans; Immunoglobulin G; Infant; Longitudinal Studies; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests | 1996 |
Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis unit.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cross Infection; Cystic Fibrosis; England; Humans; Outpatient Clinics, Hospital; Pseudomonas aeruginosa; Pseudomonas Infections | 1996 |
Necrotizing external otitis: aminoglycoside and beta-lactam antibiotic treatment combined with surgical treatment.
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Debridement; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Necrosis; Otitis Externa; Pseudomonas Infections; Recurrence; Retrospective Studies; Time Factors | 1997 |
Mechanisms of beta-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Drug Resistance, Microbial; Humans; Isoelectric Focusing; Italy; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 1998 |
Decreased virulence of a strain of Pseudomonas aeruginosa O12 overexpressing a chromosomal type 1 beta-lactamase could be due to reduced expression of cell-to-cell signaling dependent virulence factors.
Topics: Alginates; Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Decanoates; Drug Resistance, Microbial; Endopeptidases; Female; Glucuronic Acid; Hexuronic Acids; Humans; Mice; Mice, Inbred BALB C; Pancreatic Elastase; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Rhamnose; Virulence | 2000 |
Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Drug Resistance, Multiple; Humans; Lung Transplantation; Male; Middle Aged; Pseudomonas Infections | 2001 |
Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance.
Topics: Adult; Amikacin; Bacterial Outer Membrane Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Ribotyping | 2001 |
A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum beta-lactamase GES-2 in South Africa.
Topics: beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Ceftazidime; Cross Infection; Disease Outbreaks; DNA, Bacterial; Escherichia coli; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Mutagenesis, Insertional; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Random Amplified Polymorphic DNA Technique; South Africa | 2002 |
[Susceptibility of Pseudomonas aeruginosa to antibiotics isolated from patients of intensive care units in France in 1998. Resistant phenotypes to beta-lactams].
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cross Infection; France; Humans; Intensive Care Units; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fluoroquinolones; Global Health; Humans; Population Surveillance; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
Nocardicin A, a new monocyclic beta-lactam antibiotic V. In vivo evaluation.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbenicillin; Cefazolin; Escherichia coli Infections; Kidney; Liver; Male; Mice; Penicillin Resistance; Proteus Infections; Pseudomonas Infections; Serratia marcescens | 1977 |
[In vitro experiments on the working of combinations of gentamicin and beta-lactam antibiotics against Pseudonomas aeruginosa (author's transl)].
Topics: Bacteriological Techniques; beta-Lactams; Carbenicillin; Drug Combinations; Gentamicins; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin | 1975 |
High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Child; Cystic Fibrosis; Female; Humans; Isoelectric Focusing; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 1992 |
Comparison of susceptibility to beta-lactam antimicrobial agents among bacteria isolated from intensive care units.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactams; Chromatography, Gas; Cross Infection; Drug Resistance, Microbial; Fatty Acids; Humans; Intensive Care Units; Michigan; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 1992 |
Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models.
Topics: 4-Quinolones; Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; beta-Lactams; Disease Models, Animal; Dose-Response Relationship, Drug; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Gram-Negative Bacteria; Least-Squares Analysis; Mice; Mice, Inbred ICR; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Specific Pathogen-Free Organisms | 1990 |
[Resistance caused by hyperproduction of chromosomal beta-lactamase in Pseudomonas aeruginosa].
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Chromosomes, Bacterial; Drug Resistance, Microbial; Humans; Pseudomonas aeruginosa; Pseudomonas Infections | 1989 |
Beta-lactam resistant Pseudomonas aeruginosa strains emerging during therapy: synergistic resistance mechanisms.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carrier Proteins; Cell Membrane Permeability; Drug Resistance, Microbial; Hexosyltransferases; Humans; Muramoylpentapeptide Carboxypeptidase; Mutation; Penicillin-Binding Proteins; Peptidyl Transferases; Plasmids; Porins; Pseudomonas aeruginosa; Pseudomonas Infections | 1988 |
[In vivo combination effects of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa].
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; beta-Lactams; Drug Synergism; Drug Therapy, Combination; Immune Tolerance; Male; Mice; Pseudomonas aeruginosa; Pseudomonas Infections | 1986 |
Development of resistance after beta-lactam therapy.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Microbial; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections | 1987 |
Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cell Membrane Permeability; Drug Resistance, Microbial; Humans; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 1987 |
[Evaluation of the sensitivity of clinical strains of Pseudomonas aeruginosa to aminoglycoside and beta-lactam antibiotics].
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Child; Drug Resistance, Microbial; Humans; In Vitro Techniques; Pseudomonas aeruginosa; Pseudomonas Infections | 1987 |
[Preliminary study of the antagonistic effects between fosfomycin and beta-lactams on Pseudomonas aeruginosa observed on the antibiogram].
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Antagonism; Drug Therapy, Combination; Fosfomycin; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 1988 |
Comparison of bactericidal activity of selected beta-lactam antimicrobials against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Synergism; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 1988 |
[Choice of a rapidly bactericidal beta-lactamin-aminoglycoside combination in the treatment of Pseudomonas aeruginosa infections at a child intensive care unit].
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Intensive Care Units; Male; Pseudomonas Infections | 1986 |
Semisynthetic beta-lactam antibiotics. III. Effect on antibacterial activity and comt-susceptibility of chlorine-introduction into the catechol nucleus of 6-[(R)-2-[3-(3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido]-2- phenylacetamido]penicillanic aci
Topics: Animals; Anti-Bacterial Agents; Bacteria; beta-Lactams; Catechol O-Methyltransferase Inhibitors; Escherichia coli Infections; Indicators and Reagents; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Penicillins; Pseudomonas Infections; Structure-Activity Relationship | 1987 |
Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carrier Proteins; Child, Preschool; Drug Resistance, Microbial; Female; Hexosyltransferases; Humans; Male; Middle Aged; Muramoylpentapeptide Carboxypeptidase; Penicillin-Binding Proteins; Peptidyl Transferases; Pseudomonas aeruginosa; Pseudomonas Infections | 1985 |
Virulence of Pseudomonas aeruginosa strains with mechanisms of microbial persistence for beta-lactam and aminoglycoside antibiotics in a mouse infection model.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Microbial; Iron-Dextran Complex; Lethal Dose 50; Mice; Mutation; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Virulence | 1985 |
The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution?
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Cystic Fibrosis; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Pseudomonas Infections; Respiratory Tract Infections | 1985 |